Selecta Biosciences and Sarepta Therapeutics have announced that they had entered into a research license and option agreement.
Gossamer Bio shares dived on Tuesday after the company announced midstage results from its asthma and chronic rhinosinusitis studies.
Applera Corporation had an SEC Filing today saying its Board of Directors has authorized management to pursue a possible separation of the Celera Group (NYSE:CRA) from Applera. The completion of this...
Mustang Bio shares more than doubled on Thursday after the company announced a breakthrough that cured eight infants dealing with the "Bubble Boy" immune disorder.
Neurocrine Biosciences made waves in the market on Thursday morning after it announced positive results in a Phase 3 trial.
Neurocrine Bio shares dipped on Wednesday after the company announced that its midstage Tourette syndrome study did not live up to expectations.
Bio Blast Pharma was blowing away all the other bulls in Wednesday’s session, with its stock up over 150% on positive clinical results.
vTv Therapeutics watched its shares make a massive gain early on Thursday after the firm announced an exclusive licensing agreement with Newsoara Biopharma.
This article is sponsored by Corporate Citizen Project. Investment management giant BlackRock voted in 2021 in support of 149 U.S. shareholder proposals related to environmental, social, and...
Source: courtesy Making Change at Walmart and UFCWWall Street considered almost all the news from Wal-Mart Stores Inc.’s (NYSE: WMT) earings as bad. U.S. comp sales declined 1.4% in the 13-week...
Stealth Bio shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with primary mitochondrial myopathy (PMM). Specifically, the top-line...
Bluebird Bio shares have made a steady gain over the course of the year and now the firm is looking to cash in on this growth.
Enochian Biosciences shares more than doubled to start out the week after the company received a critical update from the FDA regarding its HIV treatment.
Bio-Path stock has taken a beating in the past five years. Investors obviously aren’t happy about this, and the way that management and the board of directors has handled it has been clumsy.
Highlighted stocks include AbbVie and Eli Lilly.